Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2024 | Optimizing patient selection for antibody drug conjugates in breast cancer

Eva Ciruelos • 16 May 2024
ESMO Breast 2024
Breast Cancer

Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, discusses the challenges in selecting the best treatments for HER2+ and HER2- breast cancer. She emphasizes the need to refine patient selection for each drug and determine optimal sequencing, especially as the efficacy of antibody-drug conjugates (ADCs) in later lines of therapy is not always optimal. More data on biomarkers are needed to develop the best treatment options for each patient. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eva Ciruelos

ELECTRA: elacestrant and abemaciclib in patients with ER+, HER2- breast cancer
1:43
ELECTRA: elacestrant and abemaciclib in patients with ER+, HER2- breast cancer
Eva Ciruelos • 15 Sep 2024
ELECTRA: novel combinations for HR-positive breast cancer with CNS metastases
0:42
ELECTRA: novel combinations for HR-positive breast cancer with CNS metastases
Eva Ciruelos • 15 Sep 2024
DESTINY-Breast12: enhancing outcomes for HR+/HER2+ patients with brain metastases
1:33
DESTINY-Breast12: enhancing outcomes for HR+/HER2+ patients with brain metastases
Eva Ciruelos • 15 Sep 2024
Global collaboration in biomarker-driven clinical trials at ESMO 2024
1:03
Global collaboration in biomarker-driven clinical trials at ESMO 2024
Eva Ciruelos • 15 Sep 2024

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals